← Back to All US Stocks

DBV Technologies S.A. (DBVTF) Stock Fundamental Analysis & AI Rating 2026

DBVTF Nasdaq Biological Products, (No Diagnostic Substances) I0 CIK: 0001613780
Updated This Month • Analysis: Mar 23, 2026 • SEC Data: 2025-09-30
Combined AI Rating
STRONG SELL
92% Confidence
STRONG AGREEMENT
STRONG SELL
95% Conf
STRONG SELL
90% Conf

📊 DBVTF Key Takeaways

Revenue: $5.0M
Net Margin: -2,046.0%
Free Cash Flow: $-86.2M
Current Ratio: 1.80x
Debt/Equity: 0.01x
EPS: $-0.82
AI Rating: STRONG SELL with 95% confidence
DBV Technologies S.A. (DBVTF) receives a STRONG SELL rating with 92% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $5.0M, net profit margin of -2,046.0%, and return on equity (ROE) of -193.2%, DBV Technologies S.A. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete DBVTF stock analysis for 2026.

Is DBV Technologies S.A. (DBVTF) a Good Investment?

Claude

DBV Technologies is experiencing severe financial distress with collapsing revenue (-73.6% YoY), massive operating losses (-$102M), and negative free cash flow (-$86.2M), indicating the company is burning through its cash reserves at an unsustainable rate. Despite maintaining adequate liquidity currently, the company's fundamental business model is broken with a -2046% net margin, and at current burn rates, cash runway appears critically limited.

ChatGPT

DBV Technologies' fundamentals are very weak: revenue fell 73.6% year over year while operating and net losses exceeded $102M, producing deeply negative margins and returns on capital. The balance sheet is not heavily levered and cash of $69.84M provides some support, but the current cash burn rate and lack of profitable growth make the financial profile highly fragile.

Why Buy DBV Technologies S.A. Stock? DBVTF Key Strengths

Claude
  • + Strong current liquidity position with $69.8M cash and 1.80x current ratio
  • + Minimal debt burden with only $510K long-term debt and 0.01x debt/equity ratio
  • + Modest insider activity suggests some management engagement despite challenges
ChatGPT
  • + Low financial leverage with debt/equity of 0.01x and only $0.51M of long-term debt
  • + Cash and equivalents of $69.84M still provide near-term funding flexibility
  • + Current and quick ratios of 1.80x indicate acceptable short-term liquidity

DBVTF Stock Risks: DBV Technologies S.A. Investment Risks

Claude
  • ! Revenue collapse of 73.6% YoY indicates failed commercialization or market rejection of core products
  • ! Operating cash burn of $86.2M annually unsustainable given current cash reserves of $69.8M
  • ! Massive operating losses with -2043.8% operating margin suggest fundamental business model failure
  • ! Negative ROE of -193.2% and ROA of -92.4% indicate severe capital inefficiency
  • ! Complete dependence on cash reserves for survival with no path to profitability visible
ChatGPT
  • ! Revenue contraction of 73.6% YoY suggests weak growth quality and limited commercial traction
  • ! Operating cash flow of -$86.01M and free cash flow of -$86.17M imply heavy cash burn relative to available cash
  • ! Net margin of -2046.0% and ROE of -193.2% indicate an unsustainable profitability profile

Key Metrics to Watch

Claude
  • * Quarterly revenue trend - watch for stabilization or further deterioration
  • * Operating cash flow and monthly burn rate - critical for estimating runway
  • * Cash and equivalents balance - monitor depletion timeline
  • * Operating expenses and headcount reduction initiatives - necessary for survival
  • * Product pipeline and regulatory milestone achievements - assess future revenue potential
ChatGPT
  • * Quarterly operating cash burn versus cash balance
  • * Revenue trend and any improvement in operating loss margin

DBV Technologies S.A. (DBVTF) Financial Metrics & Key Ratios

Revenue
$5.0M
Net Income
$-102.1M
EPS (Diluted)
$-0.82
Free Cash Flow
$-86.2M
Total Assets
$110.5M
Cash Position
$69.8M

💡 AI Analyst Insight

DBV Technologies S.A. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

DBVTF Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -2,043.8%
Net Margin -2,046.0%
ROE -193.2%
ROA -92.4%
FCF Margin -1,726.4%

DBVTF vs Healthcare Sector: How DBV Technologies S.A. Compares

How DBV Technologies S.A. compares to Healthcare sector averages

Net Margin
DBVTF -2,046.0%
vs
Sector Avg 12.0%
DBVTF Sector
ROE
DBVTF -193.2%
vs
Sector Avg 15.0%
DBVTF Sector
Current Ratio
DBVTF 1.8x
vs
Sector Avg 2.0x
DBVTF Sector
Debt/Equity
DBVTF 0.0x
vs
Sector Avg 0.6x
DBVTF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is DBV Technologies S.A. Stock Overvalued? DBVTF Valuation Analysis 2026

Based on fundamental analysis, DBV Technologies S.A. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-193.2%
Sector avg: 15%
Net Profit Margin
-2,046.0%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.01x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

DBV Technologies S.A. Balance Sheet: DBVTF Debt, Cash & Liquidity

Current Ratio
1.80x
Quick Ratio
1.80x
Debt/Equity
0.01x
Debt/Assets
52.2%
Interest Coverage
N/A
Long-term Debt
$510.0K

DBVTF Revenue & Earnings Growth: 5-Year Financial Trend

DBVTF 5-year financial data: Year 2021: Revenue $11.3M, Net Income -$159.6M, EPS N/A. Year 2022: Revenue $5.7M, Net Income -$97.8M, EPS $-1.78. Year 2023: Revenue $15.7M, Net Income -$96.3M, EPS $-1.24. Year 2024: Revenue $15.7M, Net Income -$72.7M, EPS $-0.76. Year 2025: Revenue $5.6M, Net Income -$113.9M, EPS $-1.17.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: DBV Technologies S.A.'s revenue has declined by 50% over the 5-year period, indicating business contraction. The most recent EPS of $-1.17 indicates the company is currently unprofitable.

DBVTF Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-1,726.4%
Free cash flow / Revenue

DBVTF Quarterly Earnings & Performance

Quarterly financial performance data for DBV Technologies S.A. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $1.1M -$27.1M $-0.24
Q2 2025 $1.2M -$27.1M $-0.31
Q1 2025 $753.0K -$27.1M $-0.26
Q3 2024 $1.1M -$16.7M $-0.17
Q2 2024 $1.2M -$20.6M $-0.26
Q1 2024 $1.4M -$20.6M $-0.22
Q3 2023 $2.1M -$16.7M $-0.17
Q2 2023 $1.5M -$16.7M $-0.26

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

DBV Technologies S.A. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$86.0M
Cash generated from operations
Capital Expenditures
$159.0K
Investment in assets
Dividends
None
No dividend program

DBVTF SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for DBV Technologies S.A. (CIK: 0001613780)

📋 Recent SEC Filings

Date Form Document Action
Mar 26, 2026 8-K d113165d8k.htm View →
Mar 26, 2026 10-K dbvt-20251231.htm View →
Mar 2, 2026 8-K d110966d8k.htm View →
Feb 2, 2026 4 xslF345X05/form4-02022026_040211.xml View →
Jan 20, 2026 8-K d74681d8k.htm View →

Frequently Asked Questions about DBVTF

What is the AI rating for DBVTF?

DBV Technologies S.A. (DBVTF) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are DBVTF's key strengths?

Claude: Strong current liquidity position with $69.8M cash and 1.80x current ratio. Minimal debt burden with only $510K long-term debt and 0.01x debt/equity ratio. ChatGPT: Low financial leverage with debt/equity of 0.01x and only $0.51M of long-term debt. Cash and equivalents of $69.84M still provide near-term funding flexibility.

What are the risks of investing in DBVTF?

Claude: Revenue collapse of 73.6% YoY indicates failed commercialization or market rejection of core products. Operating cash burn of $86.2M annually unsustainable given current cash reserves of $69.8M. ChatGPT: Revenue contraction of 73.6% YoY suggests weak growth quality and limited commercial traction. Operating cash flow of -$86.01M and free cash flow of -$86.17M imply heavy cash burn relative to available cash.

What is DBVTF's revenue and growth?

DBV Technologies S.A. reported revenue of $5.0M.

Does DBVTF pay dividends?

DBV Technologies S.A. does not currently pay dividends.

Where can I find DBVTF SEC filings?

Official SEC filings for DBV Technologies S.A. (CIK: 0001613780) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is DBVTF's EPS?

DBV Technologies S.A. has a diluted EPS of $-0.82.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is DBVTF a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, DBV Technologies S.A. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is DBVTF stock overvalued or undervalued?

Valuation metrics for DBVTF: ROE of -193.2% (sector avg: 15%), net margin of -2,046.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy DBVTF stock in 2026?

Our dual AI analysis gives DBV Technologies S.A. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is DBVTF's free cash flow?

DBV Technologies S.A.'s operating cash flow is $-86.0M, with capital expenditures of $159.0K. FCF margin is -1,726.4%.

How does DBVTF compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -2,046.0% (avg: 12%), ROE -193.2% (avg: 15%), current ratio 1.80 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2025-09-30 | Powered by Claude AI